Google
OLMA — OLEMA PHARMACEUTICALS INC (Healthcare >> Biotechnology)
OLMA FAQ
What is OLMA's ROE?
OLEMA PHARMACEUTICALS INC reports a Return on Equity (ROE) of -38.53%.
What is OLMA's dividend yield?
OLEMA PHARMACEUTICALS INC offers a dividend yield of 0.00%.
What is OLMA's Deepscope Quality Score?
Deepscope rates OLMA's overall financial quality at 15 out of 100, based on profitability, growth, debt and earnings stability.
Is now a good time to buy OLMA?
Deepscope's AI Timing Score for OLMA is 26 out of 100, indicating the relative attractiveness of buying at the current price using technical and momentum signals.
Which sector does OLMA belong to?
OLEMA PHARMACEUTICALS INC is classified under the Healthcare >> Biotechnology sector on the NASDAQ exchange.
|
USD 9.87
Price
0.12
(1.23%)
Day Change
|
|
|---|
OLMA, ファンダメンタルスコアはnot good ( ファンダメンタル = 15) そして テクニカルスコアは ...(Sign In to See)...
Loading chart...
- Signal
- UNDERPERFORM
- Signal Description
- Company financial health is Not Good
- Reason
-
ROEが低い
ROAが低い
ROEの伸びが低い
平均ROEが低い
昨年度のROEが一昨年比で低い
ROEが昨年度比で低い
ROAがROEに比べて低い
ROAの伸びが低い
昨年度のROAが一昨年比で低い
NPMが低い
NPMの伸びが低い
88 Sign in
TIMING
- Signal
- OUTPERFORM
- Signal Descri...
- Good
- Reason
- Lorem ipsum dolor sit amet
In details, quality factors are not good , financial health is not good , and ability to make profit is not good , ...
| Deepscope 分析 |
|
39% |
| In Recommendations? | Not in any sections |
| Select Rate | 0.00 From 30 days period |
| Watch Rate | 0.00 From 30 days period |
| News Score | 56 |
| Magic Formula Rank by ROA |
N/A
|
| Magic Formula Rank by ROE |
N/A
|
| Magic Formula Rank by ROIC |
N/A
|
| Price | 9.87 |
| PBV / Sector |
1.77 / 4.91
|
| Earning Per Share | -2.15 |
| PE / Sector |
N/A / 18.34
|
| PEG or PE/Growth / Sector |
N/A / 0.61
|
| Average 1M Daily Value |
15.91 M
GREAT
|
| Average 1W Daily Value |
15.37 M
GREAT
|
| Timing Factors |
|
42% |
| Financial Health |
|
45% |
| ポイントになる統計 |
|
37% |
| 配当 |
|
4% |
| 登録情報 |
| Analyze Date | 2026-06-13 11:13:37 |
| Symbol | OLMA |
| Name | OLEMA PHARMACEUTICALS INC |
| Sector | Healthcare >> Biotechnology |
| Market | NASDAQ |
| Listed Shares | 87.35 M |
| Par Value | N/A |
| Calculated From | Quarter |
| Sign | N/A |
| Market Cap (M.USD) / Sector Average | 851.64 / 9,034.83 |
| ニュース |
| Estimation Consensus | See at WSJ.com |
| Full details | See at WSJ.com |
| Chart | See in Chart feature |
| News | See at Yahoo Finance |
Address: 780 Brannan Street, San Francisco, CA, United States, 94103
Phone: 415 651 3316
Website: https://olema.com
Employees: 137
Sector: Healthcare >> Biotechnology
Description: Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women's cancers. The company's lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic ER-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, a mechanistic target of rapamycin inhibitor, and a CDK4 inhibitor that is in Phase 1b/2 clinical trial for the treatment of ER+/HER2- advanced or metastatic breast cancer. It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 which is in Phase 1 clinical trials for patients with breast and other solid tumor cancers. The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009. Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
ME vs SECTOR Healthcare >> Biotechnology
Click a bubble to view stock details · Bubble size represents market capitalization share
